IMRN
Immuron Limited
There isn't enough reported data to score IMRN yet.
IMRN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IMRN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
IMRN PE Valuation
IMRN has no meaningful PE right now: it lost money over the past year.
IMRN Forward outlook
There aren't enough analyst estimates for IMRN to show an outlook.
IMRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2022 | -$0.01 | +$0.02 |
IMRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $5M | +186% |
| Q2 2024 | $1.7M | +41% |
| Q2 2023 | $1.2M | +136% |
| Q2 2022 | $523.8K | +425% |
| Q2 2021 | $99.8K | -92% |
| Q2 2020 | $1.3M | -20% |
| Q2 2019 | $1.6M | +30% |
| Q2 2018 | $1.3M | +166% |
IMRN's revenue has grown year over year for four quarters in a row: $5M last quarter, up 304% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -73% | +124 points |
| Q2 2024 | -148% | +227 points |
| Q1 2024 | -148% | +5600 points |
| Q4 2023 | -86% | +67 points |
| Q2 2023 | -198% | -3.7 points |
| Q2 2022 | -375% | -212 points |
| Q2 2021 | -5748% | -5146 points |
| Q2 2020 | -153% | +446 points |
IMRN's operating margin was −73% last quarter, up 124 points from the same quarter a year ago, near the top of its range since 2008.
IMRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2024 | -$1.3M | +$455K |
| Q2 2023 | -$1.8M | +$379.9K |
| Q2 2022 | -$2.2M | +$635K |
| Q2 2021 | -$2.8M | -$641.6K |
| Q2 2020 | -$2.2M | -$922.5K |
| Q2 2019 | -$1.2M | +$1.2M |
| Q2 2018 | -$2.4M | +$879.1K |
| Q2 2017 | -$3.3M | -$2.3M |
IMRN has burned cash in almost every quarter: −$7M over the past year, against −$9M the year before.
IMRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3953% | +225M shares |
| 1 year | +1.4% | +3.1M shares |
| 3 years | +11834% | +229M shares |
IMRN has 231M diluted shares, up 1.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q2 2023 | $54,278 |
| Q2 2017 | — |
| Q4 2016 | — |
| Q2 2016 | — |
| Q4 2015 | — |
| Q2 2015 | — |
IMRN Net Leverage
IMRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IMRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 5.5 | Oversold |
IMRN's weekly RSI is 44 (neutral) and its Stochastic is 6 (oversold).
IMRN PE vs Healthcare Sector
IMRN has no meaningful PE right now: it lost money over the past year.
IMRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.99 | 8.1% below |
| 20 week MA | $1.12 | 19% below |
| 50 week MA | $1.02 | 11% below |
| 100 week MA | $1.44 | 37% below |
| 200 week MA | $1.78 | 49% below |
IMRN is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
IMRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.65 | $6.71 | +84% |
| 2021 | $6.71 | $2.90 | -57% |
| 2022 | $2.90 | $1.91 | -34% |
| 2023 | $1.91 | $1.88 | -1.6% |
| 2024 | $1.88 | $1.90 | +1.1% |
| 2025 | $1.90 | $0.89 | -53% |
| 2026 YTD | $0.89 | $0.91 | +2.2% |
IMRN has finished lower in four of the last six years. It's up 2.2% so far in 2026.